![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Sunday, January 03, 2016 2:47:50 AM
Wait, how can she out of the loop, but know about enough the efficacy to plan for...oh never mind :) Readyforbluesky
It's a good question, and one where I am almost completely stumped. However, remember that other drug companies/immunotherapy companies prepared manufacturing and in some cases guessed right, and in others guessed wrong. The point is the FDA is desperate, as is humanity, to find true significant breakthroughs, and close cooperation in an orphan designation might lead to appropriate prior planning, before interim results, that allow for manufacturing buildup until or unless told otherwise.
I'm still on the track that there are strict firewalls around LP and Les, at least since the resizing, and manufacturing preparation is intricately woven into a delicate balance between regulators, CROs, DMC, management and manufacturing.
You must pick up on certain language, and the language of Cognate is fairly telltale. They anticipated (back in July) that they would be done with building expansion about now, and 80 employees would be gradually added for post clinical commercialization.
We don't know they were talking about NWBO, but it seems to me they are trying to be ready as if this trial will be a success, but not get ahead of themselves more than necessary because nothing is guaranteed.
Now look at King's College, they are or have furiously worked out an initial 2 million pounds per year manufacturing agreement. Think about that, this is when enrollment is either sufficient or "very close" to complete.
Bears have given, and so has LP by the way, many examples where all this preparation simply leads to a nice new building for the next biotech to come along -- and unfortunately not for the ones who built it.
Again, manufacturing expansion could be explained by simple readiness as opposed to knowledge of good results.
The point is, due diligence isn't going to get me to what the data will eventually reveal, but the timing, particularly screening suspension and "active, not recruiting" are required by regulators and are the only likely current timing milestones that can't be fudged. But look again, Celldex thinks you can still enroll during a partial halt, but not recruit. So they read clinical trial's glossary different than what I do. All these human and biological variables turn biotech investing back into a science experiment.
Science and nature rule, even when man tinkers with it. So do your best, pick your companies and see if you're getting better at supporting the correct answers before they are determined.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM